Items stated in the management plan
Partially revisedTo determine the next development strategy based on the evaluation of the expanded cohort. Based on the funding required for development and the outlook for raising those funds, determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing.
| Item | Details |
|---|---|
| Plan name | 2030 Vision |
| Plan period | Start year Not disclosed / Final year 2030 |
| Progress against the plan | Partially revised |
| Plan assumptions | Estimated potential patient population for second-line and later AML treatment: approximately 18,750 people, Assumed drug price: ¥40,000 or ¥90,000 per day, Assumed treatment duration: 270 days, The market size estimate is the company's own estimate based on external research materials and other sources, and may differ materially from the actual market size., The development timeline may change depending on development progress, discussions with regulatory authorities, the status of partnership discussions and external conditions. |
| Key initiatives | Expansion of clinical trials (rogocekib), Focus on rare cancers, Establish value through clinical data and commercialize in the optimal format, Leverage AMED GRiT to consider a Japan-participating US-Japan joint clinical trial starting with the AE cohort, Consider a Phase 2 clinical trial plan based on the results of the expanded cohort, Determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing, Consider realizing value through a partnership, Work with partners |
| Results under the previous plan | Phase 2 start: mid-2027; application for approval: late 2028 → Not disclosed |
| Reason for revision or withdrawal | To determine the next development strategy based on the evaluation of the expanded cohort. Based on the funding required for development and the outlook for raising those funds, determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing. |
| Size of the Target Market | AML treatment market (8 major countries): $2.32 billion in 2022, forecast to reach $3.68 billion in 2032. Decline in existing drugs: $360 million; sales of new drugs: $1.72 billion. Source: GlobalData, “Acute Myeloid Leukemia (AML): Opportunity Assessment and Forecast” (published in 2023), Potential market size for second-line and later AML treatment: approximately ¥200 billion to ¥400 billion. The company's own estimate based on external research materials and other sources, Potential market size for ovarian cancer: ¥100 billion or more. The company's own estimate |
| Risks identified | Risk that the progress, timing or results of the clinical trial will differ from expectations, Risk that the progress, timing or results of new drug approval will differ from expectations, Risk that the development timeline will change due to development progress, discussions with regulatory authorities, the status of partnership discussions or external conditions, Uncertainty regarding whether future agreements will be signed, as well as their timing and terms, The initial clinical trial results are based on a small number of cases and require confirmation in additional cases, Risk of being unable to identify the patients likely to benefit, Possibility that the estimated market size will differ materially from the actual market size |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To determine the next development strategy based on the evaluation of the expanded cohort. Also, to determine how to proceed toward obtaining approval based on the funding required for development and the outlook for raising those funds.